Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

A COMMERCIALLY DURABLE BIOBANK OF GENETICALLY DIVERSE AND DIFFERENTIATION COMPETENT PRIMARY AIRWAY PROGENITOR CELLS VALIDATED FOR IN VITRO TOXICOLOGY SCREENING

Export to Word (http://www.niehs.nih.gov//portfolio/index.cfm/portfolio/grantdetail/grant_number/R43ES032523/format/word)
Principal Investigator: Pollok, Brian Andrew
Institute Receiving Award Propagenix, Inc.
Location Rockville, MD
Grant Number R43ES032523
Funding Organization National Institute of Environmental Health Sciences
Award Funding Period 15 Jan 2021 to 31 Dec 2021
DESCRIPTION (provided by applicant): Project Abstract While primary human airway epithelial cells (hAECs) have seen increasing use as models for in vitro toxicology screening, there remain severe drawbacks to their broad deployment. The limitations involve: (1) the very limited expansion potential of primary hAECs in culture results in small manufacturing lot sizes and high product costs; (2) the inability of propagated AECs to form fully differentiated, pseudostratified 3D tissue after only 4 to 5 passages in culture, thereby further exacerbating supply and cost issues; and (3) the issues of data variances due to lack of a systematic approach to donor variability and their genetic diversity. Taken together, these drawbacks result in small lot sizes of expanded cells from each donor and very expensive 3D tissue models, making it very challenging to provide or perform cost-effective, standardized in vitro toxicant screening. Propagenix has published on the ability of our EpiX™ cell culture technology to significantly enable the bioproduction of primary human airway epithelial cells possessing genomic stability and differentiative functionality over extended culture propagation. This program seeks to utilize this capability to build a human airway epithelial cell biobank that is intentional about incorporating genetic diversity and is accompanied by a preliminary dataset demonstrating parameters of toxicant response. Of particular importance will be information on toxicant response within specific subsets of airway epithelial cells and the future use of this information to create reporter cell models to decrease commercial barriers for in vitro toxicant screening.
Science Code(s)/Area of Science(s) Primary: 72 - Predictive Toxicology/Assay Development
Secondary: 03 - Carcinogenesis/Cell Transformation
Publications No publications associated with this grant
Program Officer Daniel Shaughnessy
Back
to Top